2.
目前治疗c-MET通路异常药物的临床试验
Latest clinical trials with drugs treating c-MET activation
| Agents | Clinical trial | Patients | Methods | Primary endpoint |
| NSCLC: non-small cell lung cancer; EGFR-TKI: epidermal growth factor receptor-tyrosine kinase inhibitor; IHC: immunohistochemistry; ORR: objective response rate; PFS: progression-free survival; OS: overall survival. | ||||
| Crizotinib | PROFILE 1001 Ⅰ/Ⅱ |
Advanced NSCLC patients with MET ex14 alterations |
Crizotinib 250 mg bid | ORR |
| (NCT00585195) | Advanced NSCLC patients with MET amplification |
Crizotinib 250 mg bid | ORR | |
| Cabozantinib | Ⅱ NCT01708954 |
Advanced EGFR wild-type NSCLC patients with MET IHC-positive | Cabozantinib 40 mg qd Cabozantinib 40 mg qd+Erlotinib 150 mg qd |
PFS PFS |
| Tivantinib | MARQUEE Ⅲ |
Advanced EGFR wild-type non-squamous NSCLC patients |
Tivantinib 360 mg bid+Erlotinib 150 mg qd |
OS |
| (NCT01244191) ATTENTION Ⅲ (NCT01377376) |
Advanced EGFR wild-type non-squamous NSCLC patients |
Tivantinib 360 mg bid+Erlotinib 150 mg qd |
OS | |
| Capmatinib (ICN280) | Ⅰb/Ⅱ NCT01610336 |
c-MET+ advanced NSCLC patients with acquired resistance to EGFR-TKI |
ICN280 400 mg bid+Gefitinib | ORR |
| Emibetuzumab (LY2875358) | Ⅱ NCT01900652 |
c-MET+ advanced NSCLC patients with acquired resistance to erlotinib |
Emibetuzumab monotherapy Emibetuzumab+Erlotinib 150 mg qd |
ORR ORR |